We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding Oxford Biomedica Plc (OXB) have been lively, with participants expressing mixed sentiments about the stock's future. A recurring theme is the potential underperformance of OXB's share price despite optimistic projections about its value; several investors view the stock as inherently undervalued compared to its true worth. For instance, comments like "OXB which is massively undervalued and worth at least three times as much" reflect strong belief in the company’s long-term potential. However, concerns over recent selling activity by significant shareholders, particularly M&G, have left investors cautious. M&G's recent reduction from a 7% holding to below 5% has raised questions about market confidence and liquidity in OXB shares.
In terms of financial highlights, there are optimistic projections surrounding OXB's role as a Contract Development and Manufacturing Organization (CDMO) and its potential to reach maximum capacity, which many investors believe would drive margins higher. Discussions have centered on strategic moves, such as a potential acquisition from Novo Holdings, which some investors speculate could significantly impact OXB's market positioning. As one participant aptly noted, "The sharks don’t circle if there is nothing for them to kill," indicating a belief that the market has not yet recognized OXB's full potential. While there are worries about share price volatility and the implications of larger institutional sells, the overall sentiment is cautiously optimistic, with many awaiting further developments as the market begins to stabilize.
Show more
In mid-January 2025, Oxford Biomedica PLC experienced a significant shift in its shareholder landscape as several major investors notified the company of changes in their voting rights. Briarwood Chase Management LLC, BlackRock, Inc., and M&G Plc each reported reaching thresholds in their respective holdings of Oxford Biomedica shares on January 14, 2025. These notifications highlight active investment interest in the company, suggesting a potential strategic repositioning of significant financial entities within the pharmaceutical sector.
Although the exact percentage of voting rights acquired by these investors has not been detailed, such developments may impact Oxford Biomedica's governance and strategies moving forward. The cumulative actions of major institutional shareholders underscore the ongoing interest and potential confidence in the company's operations, especially following its efforts to advance in the biomedicine space. The recurring notifications serve to reinforce Oxford Biomedica's role in attracting considerable financial backing, which could facilitate its future growth initiatives.
Show more
This is one of the most divisive elections in US history.The WSJ comments today- 'Among Harris's voters, 57% said they would feel "frightened" if Trump is elected, while 47% of Trump voters said they would feel frightened if Harris wins.'Whoever wins,the atmosphere is going to feel very raw. |
H, maybe you mis enterpreted my post. Donald simply has to win this one. Any other result would be simply catastrophic. It is that important. |
Sorry posted twice . |
All you need is love. All we need is NEWS, and lots of it. |
jez, |
My pound would be on redemptions super. In the runup to the budget a lot of people were selling assets out of fear. If redemptions from Liontrust took them below their minimum cash float then they would have no option but to sell holdings, and when they did that last year they simply sold the same tiny percentage of everything they held in the fund. |
Looks to me like Liontrust simply wanted to go under the 5% boundary, but why that's significant for them I've no idea. |
I think a lot of these websites just want traffic - i.e. they don't care if you follow the latest computer generated tip or not - they just want people who follow popular shares to click to look at the latest tip so that the website owner gets a penny from each of the advertisers on the page. Enough traffic and it must be quite lucrative else they wouldn't be able to pay Google monthly protection money to always come up near the top in the company name searches. |
if Liontrust are distressed sellers then we need to wait until they have cleared out their sale orders - is this now the case? |
My guess would simply be the budget Dom. |
If they wanted it down,and back to where it was languishing a fortnight ago, what was the breakout through £4 for? |
I'm pretty confident that OXB have at least one "proper" RNS locked and loaded. |
Yes indeed but i think its very easy for companies to concentrate on the job in hand,especially when they're involved in an esoteric science like biotech.A lot of senior management don't give two figs for the stock exchange and don't have much confidence that some teenage scribbler will fully understand their business.They probably have a point.Ultimately,the proof of the pudding will be in the eating and the reality will out.Looking at the way the Oxford Biomedica share price has moved over the last three years,you could be forgiven for believing the stock exchange is a complete lottery.I have long felt that numerous smaller companies would be better off staying private.That said,i agree,if you are listed you should make every effort to communicate your corporate message effectively. |
Steeplejack. Isn't that an argument to support companies, especially smaller companies, to use their own publicity departments to promote the company? |
I agree Dom. |
You know me well Mr President Sir, but the issue is ANY attempt to promote the share value is absent other than relying on two occasions in the year, Interims and Results. Not good enough these days. |
takeiteasy, |
Dom, |
hxxps://www.closebro |
#9036 Nor have we released any market sensitive news. Perhaps there is no equivalent to 'RNS' in French? |
Only if there are enormous funds out there which are either techmark LSE index trackers or have fund rules which include techmark LSE index constituents as an option. |
Harry, we have never left the techmark LSE index - has that helped though? :) |
With the budget / budget management campaign (pre-budget leaks of much worse) now over, I think the 3 points listed below will determine whether the new year's eve party (2 months tonight) is M&S best ever sausage rolls or Tesco value. |
In their previous sales to meet fund redemptions there has often been a news release saying that they have sold the same tiny percentage of everything they hold. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 405.50 |
Offer Price | 407.00 |
Open | 406.00 |
Shares Traded | 63,021 |
Last Trade | 16:35:17 |
Low - High | 405.00 - 408.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7380 |
PE Ratio | -2.34 |
Market Cap | 430.74M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads